Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $17.0 million.

  • Rxo's Cash & Equivalents fell 5142.86% to $17.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.0 million, marking a year-over-year decrease of 5142.86%. This contributed to the annual value of $17.0 million for FY2025, which is 5142.86% down from last year.
  • Rxo's Cash & Equivalents amounted to $17.0 million in Q4 2025, which was down 5142.86% from $25.0 million recorded in Q3 2025.
  • Over the past 5 years, Rxo's Cash & Equivalents peaked at $187.0 million during Q3 2022, and registered a low of $5.0 million during Q4 2023.
  • For the 5-year period, Rxo's Cash & Equivalents averaged around $56.5 million, with its median value being $29.0 million (2021).
  • In the last 5 years, Rxo's Cash & Equivalents plummeted by 9489.8% in 2023 and then surged by 60000.0% in 2024.
  • Over the past 5 years, Rxo's Cash & Equivalents (Quarter) stood at $29.0 million in 2021, then surged by 237.93% to $98.0 million in 2022, then tumbled by 94.9% to $5.0 million in 2023, then skyrocketed by 600.0% to $35.0 million in 2024, then crashed by 51.43% to $17.0 million in 2025.
  • Its Cash & Equivalents was $17.0 million in Q4 2025, compared to $25.0 million in Q3 2025 and $18.0 million in Q2 2025.